Laurie H Sehn

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi request reprint Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective
    Laurie H Sehn
    British Columbia Cancer Agency, and University of British Columbia, Vancouver, Canada
    Oncology (Williston Park) 19:26-34. 2005
  2. ncbi request reprint Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
    Laurie H Sehn
    Division of Medical Oncology and Pathology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada V5Z 4E6
    J Clin Oncol 23:5027-33. 2005
  3. ncbi request reprint Treatment of diffuse large B-cell lymphoma: a risk-based approach
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada
    Clin Lymphoma Myeloma 7:S14-9. 2006
  4. ncbi request reprint The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Blood 109:1857-61. 2007
  5. ncbi request reprint Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
    Blood 109:4171-3. 2007
  6. doi request reprint Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma
    Laurie H Sehn
    Division of Medical Oncology and the Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    Hematology Am Soc Hematol Educ Program 2012:402-9. 2012
  7. ncbi request reprint Chemotherapy alone for localized diffuse large B-cell lymphoma
    Laurie H Sehn
    Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Cancer J 18:421-6. 2012
  8. doi request reprint A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
    Laurie H Sehn
    British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada
    Blood 119:5118-25. 2012
  9. doi request reprint Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
    Laurie H Sehn
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 29:3396-401. 2011
  10. doi request reprint Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver Clinic, 600 W 10th Ave, Vancouver, British Columbia, Canada V5Z 4E6
    J Clin Oncol 29:1452-7. 2011

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective
    Laurie H Sehn
    British Columbia Cancer Agency, and University of British Columbia, Vancouver, Canada
    Oncology (Williston Park) 19:26-34. 2005
    ....
  2. ncbi request reprint Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
    Laurie H Sehn
    Division of Medical Oncology and Pathology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada V5Z 4E6
    J Clin Oncol 23:5027-33. 2005
    ..We conducted a population-based analysis to assess the impact of this combination therapy on adult patients with DLBCL in the province of British Columbia (BC)...
  3. ncbi request reprint Treatment of diffuse large B-cell lymphoma: a risk-based approach
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada
    Clin Lymphoma Myeloma 7:S14-9. 2006
    ..Alternative treatment strategies and newer therapies will need to be explored in the context of clinical trials...
  4. ncbi request reprint The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Blood 109:1857-61. 2007
    ..In the era of R-CHOP treatment, the R-IPI is a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials...
  5. ncbi request reprint Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
    Blood 109:4171-3. 2007
    ..The adoption of this 90-minute schedule as standard practice has had a positive impact on resource utilization...
  6. doi request reprint Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma
    Laurie H Sehn
    Division of Medical Oncology and the Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    Hematology Am Soc Hematol Educ Program 2012:402-9. 2012
    ....
  7. ncbi request reprint Chemotherapy alone for localized diffuse large B-cell lymphoma
    Laurie H Sehn
    Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Cancer J 18:421-6. 2012
    ..Ultimately, greater biologic insight into the heterogeneity of DLBCL will likely result in a personalized treatment approach that relies more on biologic characteristics than stage of disease...
  8. doi request reprint A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
    Laurie H Sehn
    British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada
    Blood 119:5118-25. 2012
    ..This study was registered at www.clinicaltrials.gov (identifier NCT00576758)...
  9. doi request reprint Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
    Laurie H Sehn
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 29:3396-401. 2011
    ..This is the first study to evaluate the safety and efficacy of bortezomib added to rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) in previously untreated advanced-stage FL...
  10. doi request reprint Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver Clinic, 600 W 10th Ave, Vancouver, British Columbia, Canada V5Z 4E6
    J Clin Oncol 29:1452-7. 2011
    ..We examined the significance of bone marrow involvement in patients treated in the current era of therapy including rituximab...
  11. doi request reprint Early detection of patients with poor risk diffuse large B-cell lymphoma
    Laurie H Sehn
    Division of Medical Oncology, Vancouver Clinic, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Leuk Lymphoma 50:1744-7. 2009
    ..These markers require further validation before clinical utility can be established. Continuous reassessment of clinical and molecular markers in the context of prospective clinical trials is necessary to ensure ongoing relevance...
  12. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
    ..We investigated whether expression of MYC protein, with or without BCL2 protein expression, could risk-stratify patients at diagnosis...
  13. doi request reprint International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era
    Alden A Moccia
    British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3383-8. 2012
    ..The IPS has not been validated in a recently treated population in which outcomes have improved compared with historic results...
  14. ncbi request reprint CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma
    Kenneth S Wilson
    Department of Medical Oncology, Vancouver Island Centre, University of British Columbia, BC, Canada
    Leuk Lymphoma 48:1102-9. 2007
    ..The addition of rituximab to CHOP chemotherapy negates the adverse prognostic influence of BCL-2 protein expression on progression free and overall survival in DLBCL...
  15. pmc Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
    Nathalie A Johnson
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, Canada
    Blood 113:3773-80. 2009
    ..CD20 and CD19 expression by FCM should be determined on all biopsies of patients with DLBCL because reduced CD20 expression cannot be reliably detected by IHC...
  16. doi request reprint Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone
    David Hui
    Department of Medical Oncology, Vancouver Cancer Centre, Vancouver, British Columbia, Canada
    Leuk Lymphoma 51:1658-67. 2010
    ..In patients with DLBCL treated with R-CHOP, the presence of extranodal disease remains prognostic, whereas a primary extranodal presentation did not affect outcome...
  17. doi request reprint MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
    Kerry J Savage
    Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, BC, Canada V5Z4E6
    Blood 114:3533-7. 2009
    ..In the R-CHOP treatment era, MYC+ DLBCLs have an inferior prognosis. Treatment regimens similar to those used in Burkitt lymphoma may be more appropriate in this patient population and need to be prospectively tested...
  18. pmc Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP
    Jesse Shustik
    Division of Medical Oncology, Laboratory Medicine, BC Cancer Agency, University of British Columbia, Vancouver, Canada
    Haematologica 95:96-101. 2010
    ..We analyzed the effect of the BCL6 rearrangement on survival in patients with diffuse large B-cell lymphoma treated with CHOP and CHOP plus rituximab (R-CHOP)...
  19. doi request reprint Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma
    Abdulwahab J Al-Tourah
    Division of Medical Oncology, Fraser Valley and Vancouver Cancer Centers and the Department of Pathology and Biostatistics, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    J Clin Oncol 26:5165-9. 2008
    ..To assess the incidence and predictive factors for development of transformed lymphoma in a population-based series of patients with follicular lymphoma (FL)...
  20. pmc CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
    Nathalie A Johnson
    Clinical Professor of Pathology, Department of Pathology, British Columbia Cancer Agency, 600 W 10 Avenue, Vancouver, BC, V5Z 4E6, Canada
    Haematologica 94:423-7. 2009
    ..CD20 protein-negative relapses occur after R-CHOP therapy but their clinical relevance is unknown...
  21. doi request reprint Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
    Kerry J Savage
    Department of Medical Oncology, University of British Columbia, Vancouver, BC, Canada
    Blood 118:4585-90. 2011
    ..0024), and OS (93% vs 84%, P = .074) favored the ABVD treatment era compared with the RT alone era. Treating limited-stage NLPHL similarly to CHL may improve outcome compared with the use of radiation alone...
  22. pmc Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse
    Diego Villa
    British Columbia Cancer Agency, 600 West 10 Ave Vancouver, BC V5Z4E6, Canada
    Haematologica 96:1002-7. 2011
    ..We reviewed the clinical features, risk of central nervous system involvement, and survival of patients with diffuse large B-cell lymphoma with involvement of the kidney at diagnosis...
  23. doi request reprint Prognostic factors in follicular lymphoma
    Thomas Relander
    Department of Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 28:2902-13. 2010
    ..There is a need for useful biomarkers for prediction of the disease course of single patients to individualize therapy, especially in the new era of chemoimmunotherapy...
  24. doi request reprint Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
    Robert Kridel
    Centre for Lymphoid Cancer, British Columbia Cancer Agency, 675 W 10th Ave, Vancouver, BC, Canada
    Blood 119:1963-71. 2012
    ..In summary, we have identified recurrent NOTCH1 mutations that provide the preclinical rationale for therapeutic inhibition of the NOTCH pathway in a subset of patients with MCL...
  25. pmc Pathogenesis of follicular lymphoma
    Robert Kridel
    Center for Lymphoid Cancer, BC Cancer Agency, Department of Pathology and Laboratory Medicine, and Division of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Invest 122:3424-31. 2012
    ..Lastly, crosstalk between neoplastic B cells and non-neoplastic immune and stromal cells in the microenvironment plays an important role in sustaining tumor cell growth, cultivating immune privilege, and promoting transformation...
  26. doi request reprint Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy
    Belinda A Campbell
    Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer 118:4156-65. 2012
    ..We retrospectively review the long-term outcomes of limited-stage DLBCL treated with abbreviated systemic therapy and radiotherapy focusing on field size: IFRT versus INRT...
  27. doi request reprint Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
    Lisa M Rimsza
    Department of Pathology, University of Arizona, Tucson, USA
    Blood 112:3425-33. 2008
    ....
  28. pmc Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
    Raquel Malumbres
    Department of Medicine, Division of Hematology Oncology and Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami, FL 33136, USA
    Blood 111:5509-14. 2008
    ..008). These findings demonstrate that the prognostic value of the 6-gene model remains significant in the era of R-CHOP treatment and that the model can be applied to routine FFPE tissue from initial diagnostic biopsies...
  29. ncbi request reprint LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab
    Yasodha Natkunam
    Department of Pathology, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 26:447-54. 2008
    ..Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab...